Trial Profile
A multicenter study, evaluating efficacy and safety of natalizumab and fingolimod in multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 17 Dec 2015 New trial record